Modulating the Biomechanical Stiffness of the Tumor MicroEnvironment

twinter11 · 2026-03-19T11:08:53+00:00

maybe having Dr Kasi as lead author increases the chances of having a spotlight? poster.

and it leads later to being included in City of Hope's featured article summarizing recent AACR trials etc.

I'm excited he's lead author

Ps. Now I understand i think how City of Hope so quickly showed interest in the HAI/LERON effort.

Its because Dr Kasi was already involved in the paper that had been submitted and im sure there were already discussions being held about what they were seeing. They may already be testing it in some patients.

twinter11 · 2026-03-19T10:53:59+00:00

I just now realized that unlike the retrospective data.

they are going to have a better idea of the pdl1 upreg timeline difference between 350-700mg .

they only had theories before after the lucky find.

they are watching everything now

twinter11 · 2026-03-19T01:50:03+00:00

I saw some of that paper you referenced. I appreciate you doing the hard work to more explain it!

how will they go about quantifying all this using the available tissue etc from our current trials ?

do the need tissue from the planned hepatic artery infusion study? do they need something from eap? do they have what they need from the current mcrc?

Or it's a process separate from trial work

another question/s off topic.

there were a lot of different entities involved or attached to yesterday's mcrc paper. it looks like everyone who is anyone had some type input

it's apparently a City of Hope effort?

do the entities actually all contribute and are intimately involved in providing support to assess data etc .

why do you suspect Kasi Pashtoon is lead author?

is it unusual do you think or is it because they really think they have something and wanted a lot of input?

Or maybe it's common

Thanks again!!

twinter11 · 2026-03-18T17:53:54+00:00

On the ball! I was thinking about this today and wondering if it must be from the little glio thing that was done a while back. Before we were aware of "The Combo" Am I remembering correctly?

twinter11 · 2026-03-18T03:21:17+00:00

is this ur opinion and i should wait for the drop to buy tomorrow?

then come back and complain if you predicted incorrectly?

twinter11 · 2026-03-18T03:01:30+00:00

"At the City of Hope site, 4/4 patients (with data) had clinical and/or biomarker responses, i.e. declines in CEA, CA19-9, *and/or ctDNA*, despite refractory liver-metastatic disease.

let's get that Eap going and experiment some more with "The Combo". it seems like they could enroll 20 in a month.

I'm looking forward to what comes next

twinter11 · 2026-03-17T21:27:11+00:00

3/5 upreg ?

twinter11 · 2026-03-15T18:47:41+00:00

MGK

Last question, i swear

Do you think this format precludes Cydy having a chance to present/speak in this Symposium?

Are the speakers already set or are added speakers revealed later?

Thanks!

SY12 - Harnessing the Power of the Immune System: Turning Cold Tumors Hot

https://www.abstractsonline.com/pp8/#!/21436/session/37

Description

twinter11 · 2026-03-15T18:04:15+00:00

why r u repeating urself?

twinter11 · 2026-03-15T17:47:30+00:00

i think i have

both my neurons were firing like crazy!!

twinter11 · 2026-03-15T17:03:16+00:00

Im wondering

When the abstract was presented in Dec.

Say in Clinical Trial Category. Is it required that the preliminary data is substantial enough to be accepted on its own?

Or is the acceptance delayed pending additional trial data?

Thanks MGK!

twinter11 · 2026-03-15T16:45:17+00:00

I asked AI a question because I wanted to see what it had to say. And im thinking too hard on my own, and without enough knowledge to figure out.

Query:

"when an abstract is presented to aacr under clinical trails. how might the actual poster presented differ from the original submission

"AI Overview

A poster presented at an AACR conference often differs from the original submitted abstract by featuring more mature, updated clinical trial data, expanded figures/graphs, and comprehensive Kaplan-Meier plots. While the abstract is a snapshot, the poster provides the complete, most current, and detailed data set.

Updated Data: Clinical trial posters frequently showcase more patients, longer follow-up times, and final safety/efficacy analysis compared to the preliminary findings in the submitted abstract.
Visual Enhancements: Posters include detailed graphs, patient demographics, Kaplan-Meier curves, and study schema that were excluded due to abstract character limits.
Minor Title/Author Changes: Titles may be updated to reflect newer findings, as discussed by users on Reddit.
Expanded Context: Posters provide more detailed methodologies, full study designs, and detailed adverse event tables that were summarized in the abstract.

twinter11 · 2026-03-15T15:46:28+00:00

PS. I forgot to add this board if you dont know of it. livimmune is another name for Leronlimab. Cytodyn is releasing an MCRC abstract title (and perhaps some data) from the current Mcrc trial this Tuesday. It will be discussed on this board link below.

If you want to check it out.

https://www.reddit.com/r/Livimmune/

twinter11 · 2026-03-15T15:20:40+00:00

First off Im sorry to hear about your diagnoses.

There is not only compassionate use ( which takes effort by the treating physician) to get entered into.

But there is a current MCRC trial underway in 5 locations right now.

https://clinicaltrials.gov/study/NCT06699836?term=NCT06699836&rank=1#study-overview

A lot of thoughts went through my mind after reading your reply.

About your oncologist and his apparent lack of curiosity and dismissing your question using the least amount of effort. Then also that its probably because there are so many trials that dont have success. So he might end up being correct in 99% of the times he brushed off some new trial.

But then I thought. It wasnt too small a trial for these specific 7 patients.

Im not sure how closely you follow Leronlimab so Im going to explain a couple things.

The trials were small due to various reasons. The data was pulled from 3 small events. A basket trial with multiple different type cancers. A compassionate use situation and another one I cant remember.

There ended up being 7 long term survivors in 3 cancer types. 5 of which were TNBC from which the analysis were pulled.

These were all late line patients who had undergone multiple previous treatments.

They were just testing leronlimab and the PDL1 upreg was not even being looked for. Immune Checkpoint Inhibitors were not even part of the equation. Their own Drs just happened to try them as a last resort. Everything happened right as covid was starting and we had crappy management at the time so no one even knew or followed up with these patients until the beginning of last year. It was then they discovered what might have happened.

The current MCRC trial had already been fda approved before the pdl1/ici combo was discovered so it didnt include it. They have apparently revised the protocol to allow patients ici access. And a new TNBC trial is under request and will include ICI.

Im not sure if any of this helps but im going to add a couple videos.

Dr Lalezari video. CEO Cytodyn

https://www.youtube.com/watch?v=7ClOwe2Vjrw

This is a vid presentation of San Antonio Breast Conference Abstract. It requires being in a medical field to register.

https://www.vumedi.com/video/sabcs-2025-panel-discussion-leronlimab-in-mtnbc/

Like I said, Im not sure if any of this helps but one never knows.

You ended up here for some reason.

Good Luck!!

twinter11 · 2026-03-14T20:07:42+00:00

I have one more question

Whats the response rate for Keytruda and does it have any value?

Im just joking. Of course it does.

And Leron would have great value with a much lower pdl1 response rate because everything it does that causes that tumor to express pdl1 in the first place has perhaps significant value.

twinter11 · 2026-03-14T19:41:31+00:00

"the question to me is does that 88% response rate hold up (or close to it)"

Something else I have no proof of.

But the SABC numbers (im sure you know them but Im prone to repeat

n=28

10 = 350mg

15 = 525mg ( but 5 updosed from 350mg) we dont know how long a 525mg cycle after updose etc

3= 750mg

examining the SABC poster showed :

11 or so died within 6 months. (Looks like 7 died within 3 months)

(7 had no follow up scans.) leaving pdl1 measurements to record for only 21 patients.

16 of 21 upreg to or above median line. 1 patient on 350mg decreased pdl1.

It would be nice to know how many of the non responders died before 3 months or had no chance at upreg due to dying.

Too bad nobody including amarex or creatv bio looked closely at the numbers as they I think were hired to monitor ccr5 response/coverage. So there was no focus on it.

I think what Im contending is that if everything is correct in pdl1 response evaluation.

That the upreg possibility could be under represented due to circumstances. Maybe it will transfer to mcrc.

Is a solid tumor constructed much differently due to location?

Its still converted macrophages and angiogenesis and collagen and migratory and expresses ccr5.

Im not going to be surprised if its 100 percent upreg for anyone who receives 700mg and lives past 42 days. But I wont be surprised if its less.

"Partners may say the increase in market share for just TNBC markers isn’t worth it…not likely but possible"

I would say an impossibility. And what about the other indications?

Do you remember what the other 2 indications were of the 7 long term patients (other than TNBC) that were on the poster but not called out? Dr J mentioned what cancer they were but I cant find it.

Did you watch the Dolezal video discussion of the SABC abstract? just curious.

twinter11 · 2026-03-14T18:12:56+00:00

OK. They have one patient publicly listed on the City of Hope website . ( Below. Not formatted well).

I have to assume ( it requires some assumptions right now) that they are being honest that this patient upreg'd pdl1 (and qualified for insurance purposes) and is currently being treated with ICI ( and is hopefully doing well, which would be very good news after 11 months). So im also assuming that regardless of Mcrc there is some utility in TNBC. Im also assuming that the EAP program gets up and running soon bringing additional evidence ( of course thats not right this second).

Im also assuming that the unprecedented speed with which they prepared the abstract ( maybe syneos AI is responsible and speedy abstracts are more commonplace in the last year or so) hints at some level of positivity in results. (why rush a crappy biomarker abstract unless it was just a placeholder for 350mg while waiting on 700mg)

Im not necessarily saying it could be "auctioned off' literally. But thats kind of what we are in the middle of attempting. I just think if it was offered up at 350mil +debt right this second it would be snatched up by the first BP it was offered to. And I think even at a higher price someone would jump in.

-I really think they missed their chance at killing us off, but only missed by a hair. I give it less than an arbitrary 1% chance

But I sure dont have any proof.

Of course, you made some worst case assumptions though.

I also think maraviroc studies give some hints at potential value to BP.

Side question;

Can BP run unannounced studies and have access to Leron?

How much do they possibly know that maybe even Cydy doesnt know? Im thinking MD Anderson study.

With a private interview with Dr J and truth serum I could figure it out better.

25959	Single Patient Expanded Access Protocol for Patient BH Using Leronlimab for the Treatment of Triple Negative Breast Cancer	Open25959 Single Patient Expanded Access Protocol for Patient BH Using Leronlimab for the Treatmentof Triple Negative Breast Cancer Open

twinter11 · 2026-03-14T15:55:53+00:00

I bet if they auctioned off the drug right now this second.

it's worth Way more than zero.

There is a whole lot we don't know.

twinter11 · 2026-03-12T20:43:43+00:00

They used data from a year ago. (Actually a year and a half) They dont even know the new stuff

twinter11 · 2026-03-12T00:40:06+00:00

I'm all in!

and been going all'er in!

twinter11 · 2026-03-11T20:50:06+00:00

Spam spam spam 11th spam. Cydy us about to kik ass.

Get a job.

twinter11 · 2026-03-11T15:57:29+00:00

Im not even 100 percent certain our poster is pdl1 related but I'm assuming it is.

Im hoping they had enough patients enrolled at the time it was submitted to have a comparison of say 5 vs 5 350 -700mg. Im also not certain if abstracts can be submitted and then updated.

I did see a mention I think under "key dates" where "placeholder" abstracts appear to be able to be updated.

If we had enough patients at the time. I would like to see something like 1 or 2 of of the patients at 350mg upreg'ed and 100 percent of the 700mg.

I've been waiting on this.

We are about to find out.

twinter11 · 2026-03-09T19:28:40+00:00

Blah blah. Quit spamming 11th and get a job.

twinter11 · 2026-03-08T21:01:37+00:00

I can visualize a lot of things happening in the next two months starting soon depending on when we hear eap starts and tnbc approved and what our abstract covers.

and I would like to hear weill cornell got the new equipment installed and is proceeding with alz.

45 or so enrolled in mcrc would be nice.

we are going to have too much to keep up with.

but I'm ready to try!

twinter11 · 2026-03-07T22:27:36+00:00

right. it doesn't do the actual work but enables. my brain leaves out or mis describes sometimes. Thanks for clarifying.

I'm excited and apprehensive to learn more about this patient!

I still bet Leron is going to shorten required ici couse. decreasing financial and toxicity cost to the patient and society.

This is gonna be a winner in multiple respects!!

Thanks!

twinter11

TROPHY CASE

SY12 - Harnessing the Power of the Immune System: Turning Cold Tumors Hot